11 results
·
19ms
·
Sources: EU EUDAMED, US FDA
ORTHOPLUG HARD BONE DESIGN
FDA 510(k)
FDA Class 2
·General, Plastic Surgery
COMPRINET, COMTESSE AND BELLAVAR STOCKINGS
FDA 510(k)
FDA Class 2
·General Hospital
LPI ML 100/532 AND ML 532 SURGICAL LASER
FDA 510(k)
FDA Class 2
·General, Plastic Surgery
AMPLATZER SEPTAL OCCLUDER
FDA Adverse Event
Malfunction
·ABBOTT MEDICAL·Product code MLV·June 12, 2023
PUMP IN STYLE ADVANCED BREAST PUMP GO TOTE
FDA Adverse Event
Malfunction
·MEDELA, INC.·Product code HGX·June 13, 2014
FAST-FIX 360 STRAIGHT NDL DLVRY SYS
FDA Adverse Event
Malfunction
·SMITH & NEPHEW INC MANSFIELD MANUFACTURING SITE·Product code GAT·February 11, 2013
QUICKFLEX MICRO LV LEAD
FDA Adverse Event
Injury
·ST JUDE MEDICAL CARDIAC RHYTHM MANAGEMENT DIVISION·Product code NIK·January 10, 2011
TherMax Blood Warmer Unit-US, PrisMax Accessory, Product Codes: 955630, 955515, 955702, 955631
FDA Recall
Open, Classified
·VANTIVE US HEALTHCARE LLC·Product code KDI·July 28, 2025
TherMax Blood Warmer Unit-US, PrisMax Accessory, Product Codes: 955630, 955515, 955702, 955631
FDA Enforcement
Class II
·Ongoing·VANTIVE US HEALTHCARE LLC·September 3, 2025
Acumatch L-Series BIPOLAR LINER, 22mm (BIPOLAR ENDOPROSTHESIS-Hip), Item Numbers: a) 100-22-19, SZ. L; b) 100-22-20, SZ. M; c) 100-22-21, SZ. N; d) 100-22-22, SZ. P; e) 100-22-23, SZ. R; f) 100-22-24, SZ. S; g) 100-22-25, SZ. T
FDA Enforcement
Class II
·Ongoing·Exactech, Inc.·July 10, 2024
Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration
FDA Enforcement
Class II
·Terminated·St Jude Medical Inc.·October 25, 2017